The results showed that the mutational status of RYR2 did not stratify the survival in all cancer types (Fig. 8A), while significant stratification can be found in bladder urothelial carcinoma (BLCA) (P = 0.00071, Fig. 8B), LUSC (P = 0.036, Fig. 8D) and uterine carcinosarcoma (UCS) (P = 0.034, Fig. 8F). This evidence concerns the gene RYR2 and bladder transitional cell carcinoma.